Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Cyclic peptides
Reexamination Certificate
2000-11-29
2009-06-30
Vogel, Nancy (Department: 1636)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Cyclic peptides
C514S002600
Reexamination Certificate
active
07553929
ABSTRACT:
The present invention relates to the delivery of biologically active molecules, such as peptides, into the interior of cells by administering to the cells a complex comprising the molecule linked to an importation competent signal peptide. Such delivery can be utilized, for example, to treat and/or prevent inflammatory conditions, e.g., but not limited to, systemic inflammatory reactions such as endotoxic shock, localized inflammatory reactions such as inflammatory skin diseases and conditions, and inflammatory diseases such as autoimmune diseases.
REFERENCES:
patent: 3710795 (1973-01-01), Higuchi et al.
patent: 5807746 (1998-09-01), Lin et al.
patent: 5811512 (1998-09-01), Hirschmann et al.
patent: 5877282 (1999-03-01), Nadler et al.
patent: 5916872 (1999-06-01), Chang et al.
patent: 5962415 (1999-10-01), Nadler et al.
patent: 6043339 (2000-03-01), Lin et al.
patent: 6090539 (2000-07-01), Haaf et al.
patent: 6495518 (2002-12-01), Hawiger et al.
patent: 2004/0147435 (2004-07-01), Hawiger et al.
patent: WO 98/11907 (1998-03-01), None
patent: WO 9834118 (1998-08-01), None
patent: WO 01/37821 (2001-05-01), None
T'Hart BA, Vervoordeldonk M, Heeney JL, Tak PP. Gene therapy in nonhuman primate models of human autoimmune disease.Gene Ther. May 2003;10(10):890-901.
Fraser CC. Exploring the positive and negative consequences of NF-kappaB inhibition for the treatment of human disease. Cell Cycle. Jun. 2006;5(11):1160-3. Epub Jun. 1, 2006.
Liu SF, Malik AB. NF-kappa B activation as a pathological mechanism of septic shock and inflammation. Am J Physiol Lung Cell Mol Physiol. Apr. 2006;290(4):L622-L645.
Tsoulfas G, Geller DA.NF-kappaB in transplantation: friend or foe? Transpl Infect Dis. Dec. 2001;3(4):212-9.
Adam et al., “Identification of specific binding proteins for a nuclear location sequence.”Nature337(6204):276-279 (Jan. 1989).
Alexander et al., “A Recombinant Human Receptor Antagonist to Interleukin 1 Improves Survival after Lethal Endotoxemia in Mice.”J. Exp. Med.173:1029-1032 (Apr. 1991).
Amura et al., “Mechanisms Involved in the Pathogenesis of Sepsis Are Not Necessarily Reflected by In Vitro Cell Activation Studies.”Infect. Immunol.66(11):5372-5378 (Nov. 1998).
Anderson, “Human gene therapy.”Nature392(6679):25-30 (Apr. 1998).
Baeuerle and Baltimore, “Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor.”Cell53(2):211-217 (Apr. 1988).
Baeuerle and Baltimore, “I kappa B: a specific inhibitor of the NF-kappa B transcription factor.”Science242(4878):540-546 (Oct. 1988).
Baeuerle and Baltimore, “The physiology of the NF-kappa B transcription factor.”Mol. Aspects Cell. Regul., published in:The hormonal control regulation of gene transcription, Chapter 20, pp. 423-446, P. Cohen & J.G. Faulkes (eds.) (1991).
Baichwal and Baeuerle, “Apoptosis: Activate NF-κ B or die?”Curr. Biol.7(1):R94-96 (Feb. 1, 1997).
Baldwin, “The NF-κB and I-κB proteins: new discoveries and insights.”Ann. Rev. Immunol.14:649-681 (1996).
Beg et al., “Embryonic lethality and liver degeneration in mice lacking the ReIA component of NF-κB.”Nature376(6536):167-170 (Jul. 13, 1995).
Böhrer et al., “Role of NF-κB in the Mortality of Sepsis.”J. Clin. Invest.100:972-985 (1997).
Branch, “A good Antisense molecule is hard to find.”TIBSpp. 45-50 (Feb. 23, 1998).
Car et al., “Interferon γ Receptor Deficient Mice Are Resistant to Endotoxic Shock.”J. Exp. Med.179:1437-1444 (May 1994).
Camarero et al., “Chemical ligation of unprotected peptides directly from a solid support.”J. Pept. Res.51(4):303-316 (Apr. 1, 1998).
Cordle et al., “Lipopolysaccharide Induces Phosphorylation of MAD3 and Activation of c-Rel and Related NF-κB Proteins in Human Monocytic THP-1 Cells.”J. Biol. Chem.268(16):11803-11810 (Jun. 5, 1993).
Dang and Lee, “Nuclear and Nucleolar Targeting Sequences of c-erb-A, c-myb, N-myc, p53, HSP70, and HIV tat Proteins.”J. Biol. Chem.264(30):18019-18023 (Oct. 25, 1989).
Delli-Bovi et al., “An oncogene isolated by transfection of Kaposi's sarcoma DNA encodes a growth factor that is a member of the FGF family.”Cell50(5):729-737 (1987).
Delli-Bovi et al., “Processing, Secretion, and Biological Properties of a Novel Growth Factor of the Fibroblast Growth Factor Family with Oncogenic Potential.”Mol. Cell. Biol.8(7):2933-2941 (Jul. 1988).
Donnelly et al., “DNA Vaccines.”Ann. Rev. Immunol.15:617-648 (1997).
Erickson et al., “Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-dieficient mice.”Nature8:560-563 (1994).
Fantuzzi and Dinarello, “The Inflammatory response in interleukin-1β-deficient mice: comparison with other cytokine-related knock-out mice.”J. Leukocyte Biol.59(4):489-493 (1996).
Felgner et al., “Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure.”Proc. Natl. Acad. Sci. USA84(21):7413-7417 (1987).
Fernandez and Bayley, “Ferrying proteins to the other side.”Nat. Biotechnol.16(5):418-420 (May 1998).
Fox,ASM News66(2):1-3 (Feb. 2000).
Friedler et al., “Backbone cyclic peptide, which mimics the nuclear localization signal of human immunodeficiency virus type 1 matrix protein, inhibits nuclear import and virus production in nondividing cells.”Biochemistry37(16):5616-5622 (Apr. 1998).
Freidman et al., “Mutagenesis of the Nuclear Localization Sequence in FGF-1 Alters Protein Stability but not Mitogenic Activity.”Biochem.&Biophy. Res. Comm.198(3):1203-1208 (Feb. 15, 1994).
Galanos et al., “Galactosamine-induced sensitization to the lethal effects of endotoxin.”Proc. Natl. Acad. Sci. USA76(11):5939-5943 (Nov. 1, 1979).
Gilmore, “Protein translocation across the endoplasmic reticulum: a tunnel with toll booths at entry and exit.”Cell75(4):589-592 (Nov. 1993).
Gilon et al., “Backbone cyclization: A new metod for conferring conformational constraint on peptides.”Biopolymers31:745-750 (May 1, 1991).
Glauser et al., “Septic Shock: pathogenesis.”Lancet338(8769):732-736 (Sep. 1991).
Goldfarb et al., “Synthetic peptides as nuclear localization signals.”Nature322(6080):641-644 (Aug. 1986).
Goldfeld et al., “Identification of a Novel Cyclosporin-sensitive Element in the Human Tumor Necrosis Factor α Gene Promoter.”J. Exp. Med.178:1365-1379 (Oct. 1993).
Goodfriend et al., “Antibodies to Bradykinin And Angiotensin: A Use of Carbodimides In Immunology Science.” 144:1344-1346 (Jun. 1964).
Hawiger, “Lipopolysaccharide-induced signal transduction and gene transcription.” In Endotoxin and the Lungs, K. Brigham, ed., Marcel Dekker, Inc., New York, Basel, Hong Kong, pp. 69-82 (1994).
Hawiger, “Noninvasive intracellular delivery of functional peptides and proteins.”Curr. Opin. Chem. Biol.3(1):89-94 (Feb. 1, 1999).
Hawley-Nelson et al., “LipofectAMINE™ Reagent: A New, Higher Efficiency Polycationic Liposome Transfection Reagent,”Focus15(3):73-83 (1992).
Haziot et al., “Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD14-deficient mice.”Immunity4(4):407-414 (Apr. 1, 1996).
Hesse et al., “Cytokine appearance in human endotoxemia and primate bacteremia.”Surg. Gynecol. Obstet.166(2):147-153 (Feb. 1, 1988).
Imamura et al., “Identification of a Heparin-binding Growth Factor-1 Nuclear Translocation Sequence by Deletion Mutation Analysis.”J. Biol. Chem.267(8):5676-5679 (Mar. 1992).
Imamura et al., “Recovery of mitogenic activity of a growth factor mutant with a nuclear translocation sequence.”Science249(4976):1567-1570 (Sep. 1990).
Increase in national hospital discharge survey
Collins Robert D.
Downs Sheila
Hawiger Jack J.
Lin Yao-Zhong
Liu Danya
Ballard Spahr Andrews & Ingersoll LLP
Vanderbilt University
Vogel Nancy
LandOfFree
Cell permeable peptides for inhibition of inflammatory... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cell permeable peptides for inhibition of inflammatory..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cell permeable peptides for inhibition of inflammatory... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4094863